Bimagrumab

DB12584InvestigationalProtein Based Therapies

Bimagrumab has been used in trials studying the treatment and supportive care of Sarcopenia, Skeletal Muscle, Mechanical Ventilation, Sporadic Inclusion Body Myositis, and Sporadic Inclusion Body Myositis (sIBM), among others.

Mechanism: Pharmacologically active on Activin receptor type-2B
Curator reviewed
Code names: BYM338 · LY3985863

Resolves to

Compound

UNIIN15SW1DIV8CAS1356922-05-8

Targets

Q13705ACVR2B

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

381Drug interactionsStructured to mechanism, not free text

13Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Bimagrumab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account